Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VRDN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViridian announces topline results from REVEAL-2 phase 3 trial of elegrobart
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Viridian disclosed topline data from its REVEAL-2 phase 3 clinical trial testing elegrobart, a subcutaneous antibody treatment, in patients with chronic thyroid eye disease. The actual trial outcomes are not detailed in the 8-K filing itself.
Item 8.01 view on EDGAR → -
medium
The company updated its corporate presentation to include the REVEAL-2 topline results, providing investors with current clinical trial data and company positioning.
Exhibit 99.2 view on EDGAR →
Summary
Viridian Therapeutics announced topline results from REVEAL-2, a phase 3 clinical trial evaluating elegrobart for chronic thyroid eye disease. Elegrobart is a subcutaneously delivered antibody targeting insulin-like growth factor-1 receptor.
While the 8-K confirms the data release, the actual trial outcomes—whether positive or negative—are not disclosed in the filing itself but are contained in the attached press release and presentation. For retail investors, this is a critical milestone for Viridian's lead program.
Phase 3 trial results typically determine whether a drug can proceed to regulatory approval, making this announcement potentially company-defining. However, the 8-K's lack of detail means investors must review the press release exhibit to understand whether the trial met its endpoints. Watch for: Follow-on disclosures about regulatory strategy, partnership discussions, or financing plans that would signal management's confidence in the data and next steps toward commercialization.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 5, 2026, Viridian Therapeutics, Inc. (the “Company”) issued a press release announcing topline data from a phase 3 clinical trial of elegrobart, a subcutaneously delivered anti-insulin-like growth factor-1 receptor antibody, in patients with chronic thyroid eye disease, which the Company refers to as the REVEAL-2 trial.
Viridian disclosed topline results from its REVEAL-2 phase 3 clinical trial evaluating elegrobart, a subcutaneous antibody targeting insulin-like growth factor-1 receptor, in patients with chronic thyroid eye disease. The company issued a press release and updated its corporate presentation to include these results. The actual trial outcomes are not detailed in the 8-K itself but are referenced in the attached exhibits.
Event · Item 9.01 — Financial Statements and Exhibits
Viridian filed exhibits including a press release and corporate presentation dated May 5, 2026.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 | Press Release, dated May 5, 2026 | 99.2
Corporate Presentation, dated May 5, 2026
The company filed two exhibits: a press release and a corporate presentation, both dated May 5, 2026. The 8-K does not disclose the content of these documents, only that they were attached as exhibits.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify